ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda, Lilly Hit With Giant Fine

by Ann M. Thayer
April 14, 2014 | APPEARED IN VOLUME 92, ISSUE 15

A Louisiana district court jury has awarded plaintiffs $1.5 million in compensatory damages and $9 billion in punitive damages to be paid by Japan’s Takeda Pharmaceuticals and its codefendant, Eli Lilly & Co. At issue was whether Takeda’s diabetes drug Actos, which Lilly copromoted, caused cancer. Takeda and Lilly intend to challenge the verdict. The trial was the first federal case to consolidate lawsuits. Three previous trials that did not involve Lilly were decided in Takeda’s favor. Although Lilly was deemed responsible for 25% of compensatory and 30% of punitive damages, the company says it is indemnified by Takeda.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment